The FDA’s decision to allow the compounding of GLP-1 weight loss drugs could undermine its public health obligations, writes ...

Drug manufacturers have increased their production, and some such as Novo Nordisk have asked the FDA to ban further production of compounded versions of their drugs. If that happens, Lavin says many ...

The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

As millions patients struggled to fill their prescriptions for the new weight loss drugs, many have turned to compounded copies.

The Ipsos survey of 1,078 adults found 24 of people would use weight-loss jabs if they were provided for free by the health service.

On 16 November 2024 at the 100th American Heart Association (AHA) Scientific Sessions in Chicago, Illinois, US, results were presented from the SUMMIT trial (NCT04847557), which evaluated the impact ...

For patients with obesity and prediabetes, three years of tirzepatide yields substantial and sustained weight reduction and a reduced risk for progression to type 2 diabetes, according to a study ...

The GLP-1 tirzepatide, the active ingredient in Eli Lilly's Mounjaro, was found to reduce the risk of heart failure by 46% among individuals with obesity, according to a study published Nov. 16 in The ...

Novo Nordisk (NVO) has reportedly launched its popular weight-loss drug Wegovy in China ahead of a rival drug by Eli Lilly ...

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking ...

For patients with obesity and prediabetes, three years of tirzepatide yields substantial and sustained weight reductio ...

Pharmacies that make customized medications are asking the federal Food and Drug Administration to protect their right to ...